Immunovant (IMVT) free cash flow

Free cash flow · fiscal 2026
-$407.32M

Immunovant (IMVT) generated free cash flow of -$407.32M in fiscal 2026 (the year ended March 31, 2026). In fiscal 2025 the figure was -$376.63M. Figures as of 18 Nov 2026, 10:33 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2026
-$407.32M
Highest on record
-$28.60Mfiscal 2019
Lowest on record
-$407.32Mfiscal 2026
Fiscal years on record
82019–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant free cash flow, in more detail

Across the 8 fiscal years on record (2019–2026), the highest was -$28.60M in fiscal 2019 and the lowest -$407.32M in fiscal 2026.

History · 8 fiscal years

Free cash flow by fiscal year

Immunovant free cash flow, year by year

Immunovant (IMVT) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2026-$407.32M—
2025-$376.63M—
2024-$214.59M—
2023-$188.39M—
2022-$106.37M—
2021-$83.54M—
2020-$53.39M—
2019-$28.60M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Immunovant and comparable companies
CompanyFree cash flowFiscal year
Bausch + Lomb BLCO-$66.00M2025
Immunovant IMVT-$407.32M2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant free cash flow: questions and answers

What is Immunovant's free cash flow?

Immunovant (IMVT) generated free cash flow of -$407.32M in fiscal 2026 (the year ended March 31, 2026). In fiscal 2025 the figure was -$376.63M.

What are the highest and lowest free cash flow figures on record for Immunovant?

Across the 8 fiscal years on record (2019–2026), the highest was -$28.60M in fiscal 2019 and the lowest -$407.32M in fiscal 2026.

How is Immunovant's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Immunovant it is on record here for 8 fiscal years, 2019 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/IMVT/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.